In this issue:
Can RT to residual disease sites prolong disease control
Activity and safety of tarlatamab plus PD-L1 inhibitor
Should BRAF and MEK inhibitors or ICIs be prioritised
Safety and efficacy of BOS172738
Osimertinib plus chemotherapy versus placebo plus chemotherapy
Long-term results of lorlatinib
Antitumour efficacy of sunvozertinib
TFS from nivolumab plus ipilimumab
Efficacy of COCOON prophylactic regimen
Taxanes versus gemcitabine
Please login below to download this issue (PDF)